# Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

> **NCT04137822** · — · NO_LONGER_AVAILABLE · sponsor: **Impatients N.V. trading as myTomorrows**

## Conditions studied

- Pancreas Cancer
- Pancreatic Cancer
- Pancreatic Cancer Stage IV
- Pancreatic Cancer Stage III

## Interventions

- **BIOLOGICAL:** IMM-101

## Key facts

- **NCT ID:** NCT04137822
- **Lead sponsor:** Impatients N.V. trading as myTomorrows
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137822, "Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04137822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*